logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
H

Hui Yu

department of medical oncology
H指数:17
被引数:1,109

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comprehensive transcriptome sequencing and biochemical studies revealed that acrolein induced lung injury in BEAS-2B cells and male rats through the lncRNA MIR155HG/miR-155-5p/CD200R1 and Nrf2/SLC7A11/GPX4 ferroptosis pathways

全面的转录组测序和生物化学研究表明，丙烯醛通过lncRNA MIR155HG/miR-155-5p/CD200R1和Nrf2/SLC7A11/GPX4铁死亡通路诱导BEAS-2B细胞和雄性大鼠的肺损伤。

Redox Biology
IF11.9
2025-08-200
OAAI
Dan Liu; Hui Yu; Zhicun Liu; Le Wang; Dawo Liu; Xiangyu Cao
Strikingly Reduced Toxicities of Fotemustine-Based Chemotherapeutics Than High-Dose Methotrexate-Containing Regimens with Comparable Efficacy

与含高剂量甲氨蝶呤方案相比，足叶乙苷基化疗药物表现出显著降低的毒性，且疗效相当。

BLOOD
IF23.1
2024-11-050
PRE
Zhang, Xudong; Fan, Mengke; Wang, Wenhua; Wu, Jingjing; Ma, Shanshan; Dong, Meng; Zhu, Linan; Wu, Xiaolong; Feng, Xiaoyan; Li, Xin; Li, Ling; Sun, Zhenchang; Wang, Xinhua; Fu, Xiaorui; Li, Zhaoming; Yan, Jiaqin; Chang, Yu; Yu, Hui; Nan, Feifei; Zhou, Zhiyuan; Ding, Mengjie; Zhang, Jieming; Zhang, Lei; Zhang, Mingzhi
Tumor response assessment by measuring the single largest lesion per organ in advanced non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitor

通过测量接受PD-1/PD-L1抑制剂治疗的晚期非小细胞肺癌患者中每个器官的单个最大病变来评估肿瘤反应

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
IF4.2
2023-10-241
OAAI
He, Li-Na; Chen, Tao; Fu, Sha; Jiang, Yongluo; Zhang, Xuanye; Chen, Chen; Du, Wei; Luo, Linfeng; Li, Anlin; Wang, Yixing; Yu, Hui; Zhou, Yixin; Wang, Yuhong; Yang, Yunpeng; Huang, Yan; Zhao, Hongyun; Fang, Wenfeng; Zhang, Li; Hong, Shaodong
Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study

奥列拉布替尼-布鲁顿酪氨酸激酶抑制剂方案治疗中枢神经系统淋巴瘤的回顾性研究

INVESTIGATIONAL NEW DRUGS
IF2.7
2022-02-0921
PRE
Wu, Jing-Jing; Wang, Wen-Hua; Dong, Meng; Ma, Shan-Shan; Zhang, Xu-Dong; Zhu, Li-Nan; Niu, Song-Tao; Ding, Meng-Jie; Zhang, Jie-Ming; Zhang, Lei; Li, Xin; Li, Ling; Sun, Zhen-Chang; Wang, Xin-Hua; Fu, Xiao-Rui; Li, Zhao-Ming; Chang, Yu; Nan, Fei-Fei; Yan, Jia-Qin; Yu, Hui; Wu, Xiao-Long; Zhou, Zhi-Yuan; Zhang, Ming-Zhi
Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial

以福莫司汀为基础的治疗与利妥昔单抗联合作为一线诱导化疗，然后进行WBRT治疗新诊断的原发性中枢神经系统淋巴瘤: 一项前瞻性II期试验

CANCER BIOLOGY & MEDICINE
IF8.4
2021-10-121
OAAI
Wu, Jingjing; Gao, Fenghua; Wang, Wenhua; Zhang, Xudong; Dong, Meng; Zhang, Lei; Li, Xin; Li, Ling; Sun, Zhenchang; Wang, Xinhua; Fu, Xiaorui; Zhu, Linan; Ding, Mengjie; Niu, Songtao; Li, Zhaoming; Chang, Yu; Nan, Feifei; Yan, Jiaqian; Yu, Hui; Wu, Xiaolong; Zhou, Zhiyuan; Zhang, Jieming; Zhang, Mingzhi

研究方向

暂未获取到该数据
M
Meichen Li
H 指数:14论文数:58被引数:546
陈
陈丽昆
H 指数:27论文数:197被引数:2,767
J
Jing Chen
H 指数:33论文数:394被引数:5,836
B
Baishen Zhang
H 指数:8论文数:28被引数:256
Z
Zhaoming Li
H 指数:34论文数:237被引数:4,115
Y
Yixin Zhou
H 指数:21论文数:87被引数:1,666
X
Xiaorui Fu
H 指数:24论文数:149被引数:2,113
F
Fred R. Hirsch
H 指数:56论文数:274被引数:1.4万
Y
Yu Chang
H 指数:32论文数:148被引数:3,637
F
Feifei Nan
H 指数:20论文数:106被引数:1,467